Which has the lower trailing P/E, ACAD or VCYT?

ACAD has the lower trailing P/E: ACAD trades at 8.91 and VCYT at 31.55. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, ACAD or VCYT?

Over the past five years, VCYT grew revenue faster — ACAD at a 19.70% CAGR versus VCYT at 28.98%.

Is ACAD or VCYT more profitable?

ACAD runs the higher net margin — ACAD at 33.42% versus VCYT at 20.37%.

How have ACAD and VCYT total returns compared?

Over the past 10 years, ACAD delivered -3.53% and VCYT delivered 19.91% annualized total return. Past performance doesn't predict future results.

Acadia Pharmaceuticals Inc. (ACAD) vs Veracyte, Inc. (VCYT)

A side-by-side comparison of Acadia Pharmaceuticals Inc. and Veracyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ACAD

Acadia Pharmaceuticals Inc.

$3.39B

$19.78HealthcareDelayed quote: Oct 6, 2026, 3:10 PM EDT

VCYT

Veracyte, Inc.

$3.52B

$44.18HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT

Total return — ACAD vs VCYT

growth of $100 · dividends reinvested · last 10y

ACAD -36.8% (-4.5%/yr)VCYT +519.9% (+20.0%/yr)VCYT compounded faster over this window

Log scale — wide-divergence pair

ACAD VCYT

ACAD vs VCYT: by the numbers

•VCYT is the larger company ($3.52B vs $3.39B market cap).
•ACAD trades at the lower trailing earnings multiple (8.91 vs 31.55 P/E), one valuation lens rather than an overall verdict.
•ACAD converts more revenue to profit (33.42% vs 20.37% net margin).
•VCYT grew revenue faster over the past five years (28.98% vs 19.70% CAGR).

Metrics side by side

Valuation

Metric	ACAD	VCYT
P/E ratio	8.91	31.55
Forward P/E	32.11	23.08
P/S ratio	2.97	6.27
P/B ratio	2.59	2.54
EV / EBITDA	31.26	28.02
FCF yield	5.15%	4.69%

Profitability

Metric	ACAD	VCYT
Gross margin	91.13%	72.09%
Operating margin	7.59%	17.03%
Net margin	33.42%	20.37%
ROE	29.12%	8.25%
ROIC	6.25%	6.72%

Growth (annualized)

Metric	ACAD	VCYT
Revenue CAGR (5Y)	19.70%	28.98%
Total return CAGR (5Y)	3.52%	1.45%

Frequently asked

Which has the lower trailing P/E, ACAD or VCYT?: ACAD has the lower trailing P/E: ACAD trades at 8.91 and VCYT at 31.55. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, ACAD or VCYT?: Over the past five years, VCYT grew revenue faster — ACAD at a 19.70% CAGR versus VCYT at 28.98%.
Is ACAD or VCYT more profitable?: ACAD runs the higher net margin — ACAD at 33.42% versus VCYT at 20.37%.
How have ACAD and VCYT total returns compared?: Over the past 10 years, ACAD delivered -3.53% and VCYT delivered 19.91% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ACAD analysis Full VCYT analysis Interactive comparison tool

Dig into the metrics

Acadia Pharmaceuticals P/E ratio Veracyte P/E ratio Acadia Pharmaceuticals ROE Veracyte ROE Acadia Pharmaceuticals operating margin Veracyte operating margin Acadia Pharmaceuticals revenue growth Veracyte revenue growth Acadia Pharmaceuticals free cash flow Veracyte free cash flow

Acadia Pharmaceuticals & Veracyte appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.